Bluebird Bio, Inc.

Bluebird Bio, Inc. is a biotechnology company focused on developing gene therapies for severe genetic diseases and cancer. The company uses gene addition to introduce a functional copy of a gene to patients with genetic disorders, as well as gene editing capabilities to modify pathogenic genes. Bluebird Bio was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Bluebird Bio, Inc. holds three contract IDVs with federal agencies. The first IDV is a Federal Supply Schedule contract awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12. This multiple-award, schedule 65 IB contract with a potential value of $300,000 allows the VA to procure drugs, pharmaceuticals, and hematology-related products from Bluebird Bio through October 2028. The second IDV is a single-award Blanket Purchase Agreement awarded by the Department of Veterans Affairs National Acquisition Center, with an estimated value of over $10.6 million through June 2024. This BPA aims to provide Zynteglo, Bluebird Bio's FDA-approved gene therapy for transfusion-dependent beta-thalassemia. The third IDV is an interim agreement under the Federal Supply Schedule 65 IB, awarded by the same VA network as the first IDV, with a potential value of $25,000 through November 2023. The awards demonstrate the VA's interest in utilizing Bluebird Bio's gene therapies and hematology products to treat veterans with rare genetic disorders and blood diseases.